Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

NCT04232397 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped the efficency is not good enough to enroll more patients

Conditions

Chronic Graft-versus-host-disease

Interventions

DRUG: Anlotinib

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine